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Abstract
Background: Thrombocytosis has been associated with COPD prevalence and increased all-cause mortality in
patients with acute exacerbation of COPD (AECOPD); but whether it is associated with morbidity in stable COPD is
unknown. This study aims to determine the association of thrombocytosis with COPD morbidity including reported
AECOPD, respiratory symptoms and exercise capacity.
Methods: Participants with COPD were included from two multi-center observational studies (SPIROMICS and
COPDGene). Cross-sectional associations of thrombocytosis (platelet count ≥350 × 109/L) with AECOPD during prior
year (none vs. any), exertional dyspnea (modified Medical Research Council (mMRC) score ≥ 2), COPD Assessment
Test (CAT) score ≥ 10, six-minute-walk distance (6MWD), and St. George Respiratory questionnaire (SGRQ) were
modeled using multivariable logistic or linear regression. A pooled effect estimate for thrombocytosis was produced
using meta-analysis of data from both studies.
Results: Thrombocytosis was present in 124/1820 (6.8%) SPIROMICS participants and 111/2185 (5.1%) COPDGene
participants. In meta-analysis thrombocytosis was associated with any AECOPD (adjusted odds ratio [aOR] 1.5; 95%
confidence interval [95% CI]: 1.1–2.0), severe AECOPD (aOR 1.5; 95% CI: 1.1–2.2), dyspnea (mMRC ≥ 2 aOR 1.4; 95%
CI: 1.0–1.9), respiratory symptoms (CAT ≥ 10 aOR 1.6; 95% CI: 1.1–2.4), and higher SGRQ score (β 2.7; 95% CI: 0.5, 5).
Thrombocytosis was also associated with classification into Global Initiative for Chronic Obstructive Lung Disease
(GOLD) group D (aOR 1.7 95% CI: 1.2–2.4).
Conclusions: Thrombocytosis was associated with higher likelihood of prior exacerbation and worse symptoms.
Platelet count, a commonly measured clinical assay, may be a biomarker for moderate-severe COPD symptoms,
guide disease classification and intensity of treatment. Future longitudinal studies investigating the role of platelets
in COPD progression may be warranted.
Trial registration: ClinicalTrials.gov: NCT01969344 (SPIROMICS) and NCT00608764 (COPDGene).
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Background
Chronic obstructive pulmonary disease (COPD) is the
third leading cause of death in the United States with
multiple systemic manifestations and a disease trajectory
affected by comorbid conditions, including cardiovascu-
lar (CV) disease [1, 2]. Platelets, long implicated in CV
disease [3], are multifunctional and play a role in many
pathophysiologic processes beyond hemostasis [4]. The
pathogenesis of sustained platelet count elevation
(thrombocytosis) involves either a myeloproliferative dis-
order or occurs as a reactive process secondary to an
underlying neoplasm, chronic infection, inflammation,
or physiologic stress [5]. Reactive thrombocytosis is a
consequence of inappropriately elevated levels of throm-
bopoietin, which is up-regulated by the inflammatory
cytokine interlukin-6, and has been associated with in-
creased soluble markers of platelet activation [5, 6]. Previ-
ous animal studies have documented the role of platelets
and platelet activation in bronchoconstriction, bronchial
reactivity, airway inflammation, and remodeling and have
corroborated clinical studies suggesting a role of increased
platelet activity in allergic and non-allergic asthmatics [7].
In COPD, thrombocytosis and markers of platelet activa-
tion have been associated with disease prevalence and, re-
cently, thrombocytosis has been associated with increased
all-cause mortality in patients with acute exacerbation of
COPD (AECOPD) [8–12]. Notably, prior research suggests
that the platelet-mortality association is independent of
cardiovascular outcomes suggesting an alternate patho-
physiologic mechanism [10]. However, the role of platelets
in COPD morbidity has not been explored. This study
investigates the association of thrombocytosis with
AECOPD, exercise capacity and patient reported respira-
tory symptoms and quality of life. The main hypothesis of
this study is that thrombocytosis is associated with worse
COPD morbidity. The large, well-characterized cohorts of
the Subpopulations and Intermediate Outcome Measures
in COPD Study (SPIROMICS) and the Genetic Epidemi-
ology of COPD study (COPDGene®) are ideal populations
in which to test this hypothesis.
Methods
Participants with COPD (post-bronchodilator ratio of
forced expiratory volume in 1 s to forced vital capacity
[FEV1/FVC] < 70%) were selected from the SPIROMICS
and COPDGene studies, two multi-center observational
cohorts with mutually exclusive recruitment. SPIROMICS
enrolled current and former smokers (≥20 pack-years) and
nonsmokers (≤1 pack-year) aged 40–80 years from twelve
clinical sites in the US with the goal of identifying inter-
mediate outcome measures that predict long-term clinical
endpoints of morbidity [13]. COPDGene enrolled self-
identified non-Hispanic whites or African-Americans aged
45–80 years from twenty-one clinical sites throughout the
US with ≥10 pack-year smoking history with the goal of
identifying genetic factors associated with COPD [14].
In SPIROMICS, cross-sectional analysis of baseline
data on complete blood count (CBC), symptoms, and re-
call of events from the year prior to the baseline visit
were ascertained. In COPDGene, CBC was collected at a
five-year follow-up visit and thus outcome data collected
at the 5-year visit (current as of September 2016) were
analyzed cross-sectionally. Thrombocytosis was defined
as platelet count of ≥350 × 109/L, a definition previously
used in the literature [15–17]. All CBCs were performed
at certified laboratories at respective sites.
Outcomes
The primary outcome of interest was patient-reported
AECOPD during the previous 12 months. Any AECOPD
included events treated with antibiotics or oral corticoste-
roids as well as severe AECOPD, defined as symptoms re-
quiring an emergency department visit or hospitalization.
Secondary outcomes of interest included dyspnea (modi-
fied Medical Research Council questionnaire, mMRC)
[18], COPD health status (COPD Assessment Test™,
CAT) [19], exercise capacity (6-min walk distance in
meters, 6MWD) [20], respiratory-specific quality of life (St
George’s Respiratory Questionnaire, SGRQ) [21], and
COPD disease burden based on Global Initiative for
Chronic Obstructive Lung Disease (GOLD) criteria for
symptom categories A-D [22]. Classification into GOLD
group D, indicative of the largest symptom burden and
highest risk for future exacerbations, was defined as at
least one severe exacerbation or ≥2 exacerbations during
the prior year and mMRC score ≥ 2 or CAT score ≥ 10.
Statistical analysis
Differences in participant demographics, respiratory func-
tion, comorbid conditions, and univariate outcomes by
presence of thrombocytosis were assessed using chi-
squared test or Fisher’s exact test for proportions and t-test
for continuous variables. Cross-sectional analyses were
performed using multivariable logistic regression to model
the relationship of thrombocytosis (dichotomized at platelet
count ≥350 × 109/L) with dichotomous outcomes including
at least one AECOPD within the prior year, at least one se-
vere AECOPD within the prior year, mMRC score ≥ 2,
CAT score ≥ 10 and classification into GOLD group D.
Multivariable linear regression was used to model the rela-
tionship of thrombocytosis with 6MWD and SGRQ score.
SPIROMICS and COPDGene were analyzed separately
then combined by meta-analysis using inverse variance
weighting to produce a pooled effect estimate.
Potential covariates were tested including age (continu-
ous), gender, race (African American vs other), highest
level of educational achievement (less than high school vs
high school or above), percentile of post-bronchodilator
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FEV1 (continuous) [23], smoking status (current vs former
smokers), ambulatory hypoxemia (oxygen saturation after
6-min walk ≤90%), inhaled corticosteroid use (ICS), body
mass index (BMI; categorical: underweight <18.5 kg/m2 vs
normal/overweight 18.5 - <30 kg/m2 vs obese ≥30 kg/m2),
anemia (dichotomous using gender-specific cutoffs of
hemoglobin), and CV comorbidities (hypertension, coron-
ary artery disease, congestive heart failure, diabetes, and
stroke) using a change in the effect estimate ≥10% be-
tween the crude and bivariate models of the association
between thrombocytosis and each outcome as criteria for
inclusion in models [24, 25]. Age, gender, education,
FEV1, smoking status, ambulatory hypoxemia, ICS use,
anemia, diabetes, congestive heart failure, and hyperten-
sion met criteria for at least one outcome in either study
and were included as covariates in all models. Because
there is no standard definition for reactive thrombocytosis,
sensitivity analysis was performed dichotomizing platelet
count at 400 × 109/L to test the robustness of the analysis.
In a subset of SPIROMICS participants who had bio-
markers measured concurrently with platelet count, the
relationship of C-reactive protein (CRP) with thrombocy-
tosis was explored using the Kruskal-Wallis test.
All analyses were conducted using SAS 9.4 (Carey, NC)
except for the meta-analysis which was performed using
Stata version 13/SE (College Station, TX). SPIROMICS
and COPDGene were approved by the institutional review
boards at each center and all participants provided written
informed consent (ClinicalTrials.gov: NCT01969344
(SPIROMICS) and NCT00608764 (COPDGene)).
Results
In SPIROMICS, Thrombocytosis was detected in 124
(6.8%) of 1820 SPIROMICS participants and 111 (5.1%)
of 2185 COPDGene participants with COPD (Fig. 1). Se-
verity of lung disease, smoking status, supplemental oxy-
gen use, and BMI were similarly distributed between
COPDGene and SPIROMICS, although COPDGene par-
ticipants were slightly older with higher prevalence of
some comorbidities including anemia, hypertension,
congestive heart failure, and diabetes. In both cohorts,
compared to participants with platelet count <350 × 109/
L, participants with thrombocytosis were more likely to
be female, have anemia and less likely to have coronary
artery disease. In SPIROMICS, participants with throm-
bocytosis were also more likely to have less than a high
school education and use supplemental oxygen while in
COPDGene they were younger and more likely to be
current smokers. Each of these trends was present but
non-statistically significant in the other cohort (Table 1).
In unadjusted analysis in both cohorts, participants with
thrombocytosis were significantly more likely to report an
AECOPD (SPIROMICS: 43.6% vs. 30.7%, p = 0.003; COPD-
Gene: 37.8% vs. 27.5%, p = 0.02) or a severe AECOPD
(SPIROMICS: 24.2% vs. 15.5%, p = 0.01; COPDGene: 23.4%
vs. 14.6%, p = 0.01) in the past year compared to the group
with lower platelet count. Those with thrombocytosis were
also significantly more likely to have worse dyspnea
(mMRC score ≥ 2), functional status, quality of life (CAT
score ≥ 10 and higher St. George Respiratory Questionnaire
score), and more likely to be classified as GOLD group D
compared to the group with lower platelet count (Table 2).
Six-minute walk distance was reduced among participants
with thrombocytosis in both cohorts but was statistically
significant only in SPIROMICS.
In adjusted analysis, compared with platelet count
<350 × 109/L, participants with thrombocytosis were 1.6
times more likely to report any AECOPD (95% confidence
interval [CI]: 1.0–2.4) and severe AECOPD (95% CI: 1.0–
2.7) in SPIROMICS, while results lost statistical signifi-
cance in COPDGene for any AECOPD (adjusted odds ra-
tio [aOR] 1.3; 95% CI: 0.8–2.1) and severe AECOPD (aOR
1.4; 95% CI: 0.9–2.4). Thrombocytosis was significantly as-
sociated with GOLD group D classification in COPDGene
and with borderline significance in participants from
SPIROMICS. Thrombocytosis was also significantly asso-
ciated with mMRC ≥2 and reduced 6MWD in SPIRO-
MICS. Among those with thrombocytosis, poorer health
status and worse quality of life were present in both
SPIROMICS and COPDGene, but differences between
groups did not reach statistical significance (Figs 2 and 3).
In meta-analysis combining both cohorts, participants with
thrombocytosis had a 1.5-fold increased odds of reporting
any AECOPD (95% CI: 1.1–2.0) or severe AECOPD (95%
CI: 1.1–2.2) during the preceding year, 1.4-fold increased
odds of moderate-severe dyspnea (mMRC ≥2; 95% CI: 1.0–
1.9), 1.6-fold increased odds of reporting worse COPD health
status (CAT score ≥ 10; 95% CI: 1.1–2.4), and were more
likely to be classified as GOLD group D (aOR 1.7; 95% CI:
1.2–2.4) (Fig. 2). Thrombocytosis was associated with worse
respiratory-specific quality of life (2.7 points higher SGRQ
score; 95% CI: 0.5, 5) but not 6MWD (Fig. 3).
Sensitivity analysis defining thrombocytosis as ≥400 ×
109/L (SPIROMICS n = 38, COPDGene n = 39) produced
similar results for any and severe AECOPD, CAT ≥10,
GOLD group D classification, and SGRQ, with results for
mMRC ≥2 of similar magnitude to the main analysis but
losing statistical significance (Table 3). Among SPIROMICS
participants who had platelet count and CRP measured at
baseline (n = 1041) participants with thrombocytosis had
significantly higher median CRP (4.6 vs. 3.0, p = 0.01).
Discussion
This appears to be the first study assessing the associ-
ation of thrombocytosis with exacerbations and patient-
reported respiratory outcomes in a large, stable COPD
cohort. In meta-analysis of two observational cohort
studies (SPIROMICS and COPDGene), thrombocytosis
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was associated with increased odds of having AECOPD
or severe AECOPD during the prior year, increased dys-
pnea, poorer health status, and worse respiratory-
specific quality of life. Participants with thrombocytosis
were also more likely to be classified in GOLD symptom
category D. These findings, which persisted after adjust-
ment for degree of airflow obstruction, CV disease, and
other comorbid chronic diseases, suggest that platelet
count, a routinely measured clinical assay, represents an
objective measure associated with recent AECOPD and
respiratory morbidity that may help guide treatment in-
tensity in patients with stable COPD.
Elevated platelet levels have previously been shown to be
more prevalent in patients with stable COPD [8], correlated
with increasing airflow obstruction [26], all-cause mortality
[10], and may be a surrogate for platelet activation [27]. In
a study of 109 patients with stable COPD, platelet count
was significantly higher than that of 51 healthy controls
and did not differ by smoking status [8]. A strong correl-
ation between platelet count and elevated levels of P-
selectin, a glycoprotein expressed and secreted by activated
platelets, has been reported [27], and a few studies have re-
ported increased platelet activation in stable COPD mea-
sured directly as platelet-monocyte aggregates or as soluble
markers of platelet activation [9, 28–30]. A recent study of
patients hospitalized for AECOPD found that thrombocy-
tosis was associated with increased risk of in-hospital and
1-year mortality independent of cardiovascular events and
correlated with respiratory failure and exacerbation severity
[10]. Among 452 individuals with stable COPD, mean
platelet count increased with increasing severity of airflow
obstruction [26]. Despite these few studies, there has been
limited data to date evaluating whether platelet levels are
associated with other measures of COPD morbidity.
Findings from this study show that thrombocytosis is
linked to several respiratory outcomes in patients with
COPD, including increased prevalence of exacerbations
and worse dyspnea and respiratory-specific quality of life.
Inclusion of CV comorbidities as a covariate in models did
not eliminate or substantially change the association be-
tween platelet count and outcomes and thus is likely not a
major mediator of the association. These findings further
support the likelihood that the pathophysiologic mechan-
ism underlying the association of platelets and COPD
morbidity is independent of increased cardiac risk. In
addition, some prior studies have reported higher platelet
counts among smokers compared to non-smokers, how-
ever findings have been inconsistent [8, 31–33]. Approxi-
mately one-third of the study participants reported
actively smoking and thrombocytosis was associated with
smoking status only in COPDGene. However, inclusion of
smoking status as a covariate in all models implies that
the association of thrombocytosis with COPD morbidity
does not simply reflect increased COPD morbidity among
current smokers.
Several alternative mechanisms have been proposed for
the role of platelets in COPD that could potentially inform
the association with AECOPD. COPD is now recognized
as a disease involving systemic inflammation [34], which
increases further during AECOPD [35] with persistent ele-
vation of inflammatory markers among non-responders,
frequent, and recurrent exacerbators [36]. Platelets act in
the inflammatory pathway by releasing pro-inflammatory
mediators and activating other inflammatory cells [37].
Prior studies have shown a weak non-significant correl-
ation between platelet count measured as a continuous
variable and CRP in both stable [8] and exacerbated [10]
COPD, however, in this study thrombocytosis was associ-
ated with significantly elevated CRP, as participants with
thrombocytosis had significantly higher median CRP (4.6
vs. 3.0, p = 0.01), implying that systemic inflammation
may play a role in the pathway between platelet elevation
Fig. 1 Consort diagram detailing the reason for exclusion of participants and ultimate classification by platelet count
Fawzy et al. Respiratory Research  (2018) 19:20 Page 4 of 9
and COPD morbidity. It remains unclear whether
AECOPD elicit a reactive thrombocytosis leading to in-
flammation through increased platelet activation and cyto-
kine release or if systemic inflammation precedes reactive
thrombocytosis and AECOPD.
Additionally, pulmonary endovascular abnormalities are
prevalent in COPD and are present even in mild disease
[38]. Studies have shown endothelial dysfunction, intimal
thickening, as well as reduced and narrowed vasculature in
COPD, leading to impaired relaxation and gas exchange
and promotion of platelet rolling and aggregation [39–41].
Platelets also play a role in angiogenesis, maintaining vascu-
lar integrity, and release vasoactive substances [37]. Prior
studies reported increased platelet count among hypoxic
patients with airflow obstruction [42], possibly due to in-
creased interaction and activation of platelets driven by
compromised endothelium. The present study demon-
strates that thrombocytosis was independently associated
with AECOPD after controlling for ambulatory hypoxemia.
While this may suggest that the association of platelets with
morbidity is independent of endothelial dysfunction, hypox-
emia is multifactorial and only one of several physiologic
Table 1 Baseline characteristics and outcomes of SPIROMICS and COPDGene participants by platelet count
SPIROMICS COPDGene
Characteristics [n (%) or
mean ± standard deviation]
Platelet Count
<350 × 109/L (n = 1696)
Platelet Count
≥350 × 109/L (n = 124)
p-value Platelet Count
<350 × 109/L (n = 2074)
Platelet Count
≥350 × 109/L (n = 111)
p-value
Age 65.2 ± 8 64.9 ± 7.6 0.7 68.3 ± 8.3 66.1 ± 8.6 0.01
Female 705 (41.6) 72 (58.1) 0.0003 894 (43.1) 72 (64.9) <0.0001
Race: Black 254 (15.1) 21 (16.9) 0.6 456 (22) 27 (24.3) 0.6
Less than high
school education
647 (38.3) 60 (48.8) 0.02 225 (10.9) 18 (16.2) 0.08
FEV1% predicted
(post-bronchodilator)
61.3 ± 23.1 57.3 ± 21.5 0.07 60.5 ± 22.7 57 ± 22.6 0.1
GOLD I (FEV1% predicted
≥ 80%)
380 (22.4) 20 (16.1) 0.2 432 (20.8) 18 (16.2) 0.2
GOLD II (FEV1% predicted
50–79%)
753 (44.4) 55 (44.4) 933 (45) 50 (45.1)
GOLD III (FEV1% predicted
30–49%)
389 (22.9) 38 (30.7) 508 (24.5) 26 (23.4)
GOLD IV (FEV1% predicted
< 30%)
174 (10.3) 11 (8.9) 201 (9.7) 17 (15.3)
Current smoker 569 (34.2) 47 (38.5) 0.3 679 (32.8) 49 (44.1) 0.01
Oxygen saturation≤ 90%
after 6-min walk
541 (33.7) 43 (38.4) 0.3 653 (32.5) 33 (30.8) 0.7
Supplemental home oxygen 391 (23.2) 38 (30.1) 0.05 512 (24.7) 30 (27) 0.6
Anemia: Hemoglobin (g/dL)
<13 (men) or <12 (women)
140 (8.3) 20 (16.1) 0.01 262 (12.6) 35 (31.5) <0.0001
At least 2 cardiovascular
comorbidities
303 (17.9) 21 (16.9) 0.8 484 (23.3) 20 (18) 0.2
Hypertension 853 (50.8) 62 (50.8) 1 1122 (54.2) 64 (57.7) 0.5
Coronary arterial disease 181 (10.8) 5 (4.1) 0.02 246 (11.9) 4 (3.6) 0.008
Congestive heart failure 53 (3.2) 2 (1.6) 0.6 111 (5.4) 8 (7.2) 0.4
Diabetes 226 (13.5) 22 (18) 0.2 353 (17) 13 (11.7) 0.1
Stroke 73 (4.4) 6 (4.9) 0.8 82 (4) 3 (2.7) 0.8
Body Mass Index (BMI, kg/m2) 27.4 ± 5.3 27.2 ± 6.1 0.8 28 ± 6.1 27.2 ± 6.3 0.2
Underweight
(BMI < 18.5 kg/m2)
62 (3.7) 9 (7.3) 0.1 56 (2.7) 7 (6.3) 0.06
Normal/Overweight
(BMI 18.5–30 kg/m2)
1108 (65.3) 75 (60.5) 1355 (65.3) 74 (66.7)
Obese (BMI≥ 30 kg/m2) 526 (31) 40 (32.3) 663 (32) 30 (27)
Inhaled corticosteroid use 780 (46.5) 66 (53.7) 0.1 886 (43.1) 58 (53.2) 0.03
GOLD Global Initiative for Chronic Obstructive Lung Disease. Boldface indicates statistical significance at p < 0.05. Platelet count was measured at baseline in
SPIROMICS and at 5-year follow-up in COPDGene
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manifestations of endothelial abnormalities. More precise
and direct measures of endothelial dysfunction are
required to elucidate platelet-endothelial interactions
in COPD.
There are limitations to this study. Given the cross-
sectional nature of this investigation, it is not possible to
determine temporality and it remains unclear whether
thrombocytosis is a risk factor for or physiologic reaction to
AECOPD or disease severity. Without a clear clinical cut-
off for defining thrombocytosis, misclassification based
upon the chosen value is possible, however, any misclassifi-
cation would attenuate the associations described in this
Fig. 2 Association of thrombocytosis (platelet count ≥350 × 109/L) with COPD morbidity (dichotomous outcomes). aOR: adjusted odds ratio;
mMRC: modified medical research council questionnaire; CAT: COPD assessment test; GOLD: Global Initiative for Chronic Obstructive Lung
Disease. Statistical significance (p < 0.05) denoted by asterisk
Table 2 Univariate associations of thrombocytosis (platelet count ≥350 × 109/L) with COPD morbidity










Any Acute Exacerbation of COPD during the prior year 30.7% 43.6% 0.003* 27.5% 37.8% 0.02*
Severe Acute Exacerbation of COPD during the prior year 15.5% 24.2% 0.01* 14.6% 23.4% 0.01*
Modified Medical Research Council (mMRC)
Questionnaire score≥ 2
31.4% 47.5% 0.0002* 52.9% 64% 0.02*
COPD Assessment Test (CAT) score≥ 10 72.4% 86.2% 0.001* 66.4% 77.5% 0.02*
GOLD symptom group D 20% 33% 0.0009* 19.4% 33.3% 0.0004*
6-min walk distance in meters 395 ± 128 352 ± 134 0.007a 371 ± 124 358 ± 118 0.3a
St. George Respiratory Questionnaire score 38 ± 20 44 ± 19 0.0002a 32 ± 22 38 ± 24 0.005a
GOLD Global Initiative for Chronic Obstructive Lung Disease. *chi-squared test; at-test
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study toward the null. Furthermore, these findings were ro-
bust to a sensitivity analysis using a higher cutoff for defin-
ing thrombocytosis, even though analysis of mMRC score
lost statistical significance owing to the low prevalence (ap-
proximately 2%) of platelet count greater than 400 × 109/L.
In a substudy of SPIROMICS participants (n = 98) under-
going repeat baseline evaluation 2–4 weeks from the ori-
ginal visit a change in exacerbation history recall of the
previous year occurred in 30% and 13% of participants
reporting total and severe exacerbations respectively, with
repeatability of other measures ranging from fair (mMRC)
to excellent (SGRQ) [43].
Conclusions
Thrombocytosis was independently associated with worse
COPD morbidity, including higher likelihood of prior ex-
acerbation, worse patient reported outcomes, and GOLD
group D classification. While the mechanism behind this
association remains unclear and requires additional inves-
tigation, increased platelet activation perpetuating local
and systemic inflammation may play a prominent role in
COPD morbidity. These study results suggest that platelet
count, a routinely measured clinical assay, may be an
important biomarker associated with AECOPD and re-
spiratory morbidity in patients with previously stable
COPD that can aid in classification of disease severity and
treatment intensity.
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